Neglected 80-year-old antibiotic is effective against multi-drug resistant bacteria
Better purification overcomes original renal toxicity concerns
May 16, 2023
An old antibiotic may provide much-needed protection against multi-drug resistant bacterial infections, according to a new study publishing May 16th in the open access jou rnal PLOS Biology by James Kirby of Harvard Medical School, US, and colleagues. The finding may offer a new way to fight difficult-to-treat and potentially lethal infections.
Nourseothricin is a natural product made by a soil fungus, which contains multiple forms of a complex molecule called streptothricin. Its discovery in the 1940s generated high hopes for it as a powerful agent against Gram-negative bacteria, which, due to their thick outer protective layer, are especially hard to kill with other antibiotics. But nourseothricin proved toxic to kidneys, and its development was dropped. However, the rise of antibiotic-resistant bacterial infections has spurred the search for new antibiotics, leading Kirby and colleagues to take another look at nourseothricin.
Nourseothricin is a natural product made by a soil fungus, which contains multiple forms of a complex molecule called streptothricin. Its discovery in the 1940s generated high hopes for it as a powerful agent against Gram-negative bacteria, which, due to their thick outer protective layer, are especially hard to kill with other antibiotics. But nourseothricin proved toxic to kidneys, and its development was dropped. However, the rise of antibiotic-resistant bacterial infections has spurred the search for new antibiotics, leading Kirby and colleagues to take another look at nourseothricin.
Early studies of nourseothricin suffered from incomplete purification of the streptothricins. More recent work has shown that the multiple forms have different toxicities with one, streptothricin-F, significantly less toxic, while remaining highly active against contemporary multidrug-resistant pathogens. Here, the authors characterized the antibacterial action, renal toxicity, and mechanism of action of highly purified forms of two different streptothricins, D and F. The D form was more powerful than the F form against drug-resistant Enterobacterales and other bacterial species, but caused renal toxicity at a lower dose. Both were highly selective for Gram-negative bacteria.
Using cryo-electron microscopy, the authors showed that streptothricin-F bound extensively to a subunit of the bacterial ribosome, accounting for the translation errors these antibiotics are known to induce in their target bacteria. Interestingly, the binding interaction is distinct from other known inhibitors of translation, suggesting it may find use when those agents are not effective.
“Based on unique, promising activity,” Kirby said, “we believe the streptothricin scaffold deserves further pre-clinical exploration as a potential therapeutic for the treatment of multidrug-resistant, Gram-negative pathogens.”
Kirby adds, “Isolated in 1942, streptothricin was the first antibiotic discovered with potent gram-negative activity. We find that not only is it activity potent, but that it is highly active the hardiest contemporary multidrug-resistant pathogens and works by a unique mechanism to inhibition protein synthesis.”
Contact: James Kirby, jekirby@bidmc.harvard.edu
Image Caption: Streptothricin-F (yellow spheres) bound to the 16S rRNA (green) of the bacterial ribosome impinges on the decoding site where tRNA (purple) binds to the codon of the mRNA (blue). This interaction leads to translation infidelity (scrambled protein sequences), and the resulting death of the bacterial cell. The image was created by overlay of PDB 7UVX containing streptothricin-F (this manuscript) with PDB 7K00 containing mRNA and A-site tRNA (ref DOI: 10.7554/eLife.60482).
Image Credit: James Kirby (CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/); Zoe L Watson et al., 2023, eLife, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)
Image URL: https://plos.io/40LZRD2
Citation: Morgan CE, Kang Y-S, Green AB, Smith KP, Dowgiallo MG, Miller BC, et al. (2023) Streptothricin F is a bactericidal antibiotic effective against highly drug-resistant gram-negative bacteria that interacts with the 30S subunit of the 70S ribosome. PLoS Biol 21(5): e3002091. https://doi.org/10.1371/journal.pbio.3002091
Author Countries: United States
Funding: see manuscript
Competing interests: The authors have declared that no competing interests exist.
About PLOS Biology
PLOS Biology is an open-access, peer-reviewed journal published by PLOS, featuring research articles of exceptional significance, originality, and relevance in all areas of biology. For more information visit http://journals.plos.org/plosbiology/, or follow @PLOSBiology on Twitter.
Media and Copyright Information
For information about PLOS Biology relevant to journalists, bloggers and press officers, including details of our press release process and embargo policy, visit http://journals.plos.org/plosbiology/s/press-and-media.
PLOS Journals publish under a Creative Commons Attribution License, which permits free reuse of all materials published with the article, so long as the work is cited.
About PLOS
PLOS is a nonprofit, Open Access publisher empowering researchers to accelerate progress in science and medicine by leading a transformation in research communication. We’ve been breaking boundaries since our founding in 2001. PLOS journals propelled the movement for OA alternatives to subscription journals. We established the first multi-disciplinary publication inclusive of all excellent research regardless of novelty or impact, and demonstrated the importance of open data availability. As Open Science advances, we continue to experiment to provide more opportunities, choice, and context for readers and researchers. For more information, visit https://www.plos.org/who-we-are.
Disclaimer
This press release refers to upcoming articles in PLOS Biology. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
Source:
http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002091
"Reproduced with permission - PLOS"
PLOS
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
